<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>STI MeG-CLS-038</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="sexually-transmitted-infections-sti">Sexually transmitted infections (STI)</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Sexually transmitted infections are infections that can be transferred through sexual contact, from one individual to another. They include: syphillis, gonorrhoea, chlamydia, chancroid, genital herpes, genital warts, <em>Trichomonas vaginalis</em> and HIV (discussed in a separate guideline).</p>
<p>Majority of people with STIs are asymptomatic or may present with non-specific signs and symptoms. Early detection and treatment are however of great significance as some STIs may result in serious long-term reproductive health problems.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><p>Nurses</p></li>
<li><p>Doctors</p></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><p>Gate Clinic</p></li>
<li><p>OPD</p></li>
<li><p>Ward</p></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guideline provides information on the diagnosis and treatment of common STIs using a syndromic approach. Patients with typical presentation do not require further workup beyond HIV screening unless specific indications are present. Treatment involves use of oral and/or parenteral antibiotics. Inpatient therapy may be indicated in some patients with acute pelvic inflammatory disease.</p>
<h2 id="limitations">Limitations</h2>
<p>Culture and sensitivity studies are currently not available at Keneba and Basse<strong>.</strong></p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<h3 id="men">Men:</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Urethral discharge: It is usually accompanied by dysuria. Frequency and itchy sensation may also be present</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Genital ulcers</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Inguinal mass</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Scrotal swelling</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Painful micturition</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>May be asymptomatic</p>
</div></li>
</ul>
<h3 id="women">Women:</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Vaginal discharge</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Genital ulcers</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Inguinal mass</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Lower abdominal pain</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Fever</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>May be asymptomatic</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<h2 id="following-a-general-and-abdominal-examination-in-depth-examination-of-the-genitalia-should-be-undertaken.">Following a general and abdominal examination, in-depth examination of the genitalia should be undertaken.</h2>
<h3 id="men-1">Men:</h3>
<p>Inspection: the penis should be inspected. The opening of the urethra should be examined for discharge. Discharge should be milked-out if none is seen at initial inspection. The phallus skin should be examined for ulcers. If ulcers are present, note their number and the presence of any tenderness.</p>
<p>Palpation: palpate for inguinal lymph nodes</p>
<h3 id="women-1">Women:</h3>
<p>Inspection: the vulva region should be inspected first for any discharge, ulcers or warts. Following this, a speculum examination should be carried out. Inspect the cervix, and vagina as the speculum is eased out. The origin of vaginal discharge is of importance. If it is seen to come from the cervix, gonorrhoeal and chlamydial infections are more likely.</p>
<h3 id="important-things-to-look-for">Important things to look for </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Colour and consistency of discharge if present</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Number of ulcers if present and associated tenderness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Presence of inguinal lymph nodes</p>
</div></li>
</ul>
<h2 id="differential-diagnoses">Differential diagnoses</h2>
<p>Urethral discharge: gonorrhea, chlamydia</p>
<p>Genital ulcer: syphilis, chancroid, granuloma inguinale, lymphogranuloma venereum (LGV), herpes simplex virus</p>
<p>Scrotal swelling: testicular torsion, epididymitis (gonorrhea, chlamydia)</p>
<p>Vaginal discharge: candidiasis, bacterial vaginosis, chlamydia, gonorrhea, <em>Trichomonas vaginalis</em></p>
<p>Neonatal conjunctivitis: gonorrhea, chlamydia, other organisms: <em>Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus spp</em></p>
<h2 id="investigations">Investigations</h2>
<p>HIV Screen should be offered to all patients.</p>
<p>Syndromic management does not require other investigations to be done. If there are specific indications appropriate investigations might include:</p>
<p>FBC, Urethral swab M,C&amp;S, High vaginal swab M,C&amp;S, Endocervical swab M,C&amp;S</p>
<p>Test for syphilis (VDRL, TPHA) – especially for patients with genital ulcer.</p>
<h2 id="management">Management</h2>
<p>Ask all patients about their sexual partners.</p>
<p>Describe sexual transmission of infections and advise on reducing the risk of this by being faithful to one partner who is also faithful (or group of partners in a polygamous marriage) and by condom use if this is not possible.</p>
<p>Ask patients to bring partners to the clinic for treatment Advise them to abstain from sexual contact until all partners have been treated.</p>
<p>Provide pre-test counselling for HIV testing and offer a test if accepted.</p>
<p>Advise patients to seek further medical attention if their symptoms have not resolved by a week after treatment. Give them an appointment 7 days later to check on their progress and to facilitate partner management.</p>
<p>A syndromic approach to management is currently advocated for by WHO in low-resource settings due to the lack of appropriate investigations. This involves the use of certain signs and symptoms to guide treatment.</p>
<p>There are 6 syndromes:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Urethral discharge</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vaginal discharge</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Scrotal swelling</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Genital ulcer</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Lower abdominal pain</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Neonatal conjunctivitis</p>
</div></li>
</ul>
<p>Note that urethral discharge, scrotal swelling and vaginal discharge coming from the cervix are all treated in the same way.</p>
<h3 id="urethral-discharge-scrotal-swelling-vaginal-discharge">Urethral discharge, scrotal swelling, vaginal discharge</h3>
<p>Examine men complaining of discharge to identify it. If none is seen, gently milk the penis to see if discharge is produced. Swab the discharge and send for urgent microscopy</p>
<p>Examine men with scrotal swelling to exclude other causes of scrotal swelling, such as trauma, testicular torsion or tumour. Consider requesting an ultrasound.</p>
<p>All women with vaginal discharge should be examined with a speculum and a high vaginal swab taken and sent for microscopy.</p>
<p>Treat patients thought to have STI as the cause of these symptoms with Ciprofloxacin 500 mg orally as a single dose PLUS Doxycycline 100 mg orally BD for 7 days.</p>
<p>If a woman is pregnant and cannot take these medications, use azithromycin 2 g orally as a single dose.</p>
<p>Recommend bed rest and scrotal support for men with scrotal swelling until the inflammation has reduced.</p>
<h3 id="vaginal-discharge-not-from-the-cervix">Vaginal discharge (not from the cervix)</h3>
<p>Treat this with Metronidazole 500 mg BD for 7 days (OR Metronidazole 2 g as a single dose) PLUS Clotrimazole 200 mg intravaginally OD for 3 days (OR Fluconazole 150 mg orally as a single dose).</p>
<h3 id="genital-ulcer">Genital ulcer</h3>
<p><strong>Vesicular, multiple or recurrent</strong>: Aciclovir 400 mg TDS for 7 days</p>
<p><strong>Non-vesicular:</strong> Doxycycline 100 mg twice daily for 15 days PLUS Ciprofloxacin 500 mg twice daily for 3 days. This covers chancroid, LGV and syphilis.</p>
<p>If the patient is pregnant, then use im Ceftriaxone 250 mg as a single dose PLUS erythromycin 500 mg QDS for 14 days.</p>
<h3 id="lower-abdominal-pain">Lower abdominal pain</h3>
<p>Lower abdominal pain may be caused by pelvic inflammatory disease (PID). There may also be pain during intercourse, vaginal discharge, dysuria, increased length and frequency of menses, increased pain during menses, fever, nausea and vomiting.</p>
<p>Women complaining of lower abdominal pain should be fully examined. On pelvic examination there may be adnexal tenderness, cervical motion tenderness and visible discharge. They may also have a tender pelvic mass, and rebound tenderness.</p>
<p>Inpatient care of patients with acute pelvic inflammatory disease should be considered when one or more of the following are present:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Uncertain diagnosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Failure to exclude surgical emergencies for example appendicitis and ectopic pregnancy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Suspected pelvic abscess</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>A severe illness which will prevent outpatient management</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>A pregnant patient</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Inability to tolerate outpatient regimen</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Failure to respond to therapy on an out-patient basis.</p>
</div></li>
</ul>
<p><strong>Outpatient management:</strong> Ceftriaxone 250 mg IM as a single dose PLUS Doxycycline 100 mg orally BD for 14 days <em><strong>PLUS</strong></em> Metronidazole 500 mg orally BD for 14 days</p>
<p>Inpatient management: Ceftriaxone 250 mg by intramuscular injection OD PLUS Doxycycline, 100mg orally or by intravenous injection BD PLUS Metronidazole 500mg orally or iv TDS.</p>
<p>Inpatient therapy should be continued until at least 2 days after the patient has improved, after which doxycycline should be given at 100mg orally, twice daily for 14 days.</p>
<h3 id="ophthalmia-neonatorum">Ophthalmia neonatorum</h3>
<p>Ceftriaxone 50 mg/kg by intramuscular injection as a single dose, to a maximum of 125 mg PLUS Erythromycin syrup 50 mg/kg per day orally, in 4 divided doses for 14 days.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<p>Refer the following patients to see a doctor:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>A man with persistent or recurrent urethritis.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients with genital ulcers that do not improve with treatment.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients with genital ulcers where the diagnosis is unclear.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Men with inguinal mass which is fluctuant or of uncertain cause.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Men with scrotal swelling of uncertain cause.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Women with vaginal discharge unless you can do a speculum and pelvic examination yourself.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Women with lower abdominal pain unless you can do a pelvic examination yourself.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p><a href="http://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)"><span data-custom-style="Hyperlink">http://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)</span></a></p>
<p>WHO guidelines for management of sexually transmitted infections <a href="http://apps.who.int/medicinedocs/en/d/Jh2942e/3.1.html"><span data-custom-style="Hyperlink">http://apps.who.int/medicinedocs/en/d/Jh2942e/3.1.html</span></a></p>
<p><a href="http://apps.who.int/medicinedocs/documents/s22268en/s22268en.pdf"><span data-custom-style="Hyperlink">http://apps.who.int/medicinedocs/documents/s22268en/s22268en.pdf</span></a></p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Azeezat Sallahdeen</th>
<th>Date: 22 May 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 11 June 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td></td>
</tr>
<tr class="even">
<td>2.0</td>
<td>Adapted from previous version and MeG-CLS-016 to combine into one document relevant to all areas</td>
<td>31 July 2020</td>
</tr>
<tr class="odd">
<td>2.1</td>
<td>Executive summary added</td>
<td>31 July 2020</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
